Literature DB >> 12439163

Paranasal sinus malignancies: an 18-year single institution experience.

Larry L Myers1, Brian Nussenbaum, Carol R Bradford, Theodoros N Teknos, Ramon M Esclamado, Gregory T Wolf.   

Abstract

OBJECTIVES: To characterize a single institution experience with management of paranasal sinus malignancies during an 18-year time period, report long-term survival rates, and identify prognostic factors. STUDY
DESIGN: Retrospective chart review.
METHODS: Studied were 141 patients treated for a paranasal sinus malignancy at a single institution from 1980 to 1997 with a minimum 3-year follow-up. Gender, age, TNM stage, anatomic site, pathology, treatment, and recurrence rates were reviewed. Multivariate analysis was performed to determine factors affecting survival.
RESULTS: The male to female ratio was 1.6:1, and the median patient age was 60 years. Most patients presented with T3/T4 or locally advanced disease (88%), N0 status (96%), and M0 status (96%). The maxillary sinus was the most commonly affected site (70%), followed by the ethmoid sinus (26%). The most common malignancy was squamous cell carcinoma (51%), followed by adenoid cystic carcinoma (12%) and adenocarcinoma (11%). Sixty-two percent of this study group underwent surgery as part of a multimodality curative treatment plan or alone as curative treatment. Eighteen patients (13%) had unresectable local disease and received non-surgical palliative treatment. Kaplan-Meier analysis revealed the 5-year and 10-year disease-specific survival was 52% and 35%, respectively. Multivariate analysis revealed T4 stage (P =.005), N-positive stage (P =.009), and M-positive stage (P =.018) negatively impacted survival. Seventy-two patients (51%) developed recurrent disease at a median time of 336 days after initial treatment.
CONCLUSIONS: Most patients with paranasal sinus malignancies presented with locally advanced disease. Advanced T stage, regional, and distant metastasis are highly predictive of poor survival. Recurrence rate is high and typically occurs within the first year after treatment.

Entities:  

Mesh:

Year:  2002        PMID: 12439163     DOI: 10.1097/00005537-200211000-00010

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  28 in total

1.  Recurrent maxillary sinus cancer with only adrenal metastasis.

Authors:  Hye Jung Chang; Joon-Young Hur; Kyu Yeoun Won; Boksoon Chang; Ha Yeon Lee
Journal:  Mol Clin Oncol       Date:  2017-09-20

2.  SUVmax on FDG-PET is a predictor of prognosis in patients with maxillary sinus cancer.

Authors:  Hiroshi Doi; Kazuhiro Kitajima; Kazuhito Fukushima; Yusuke Kawanaka; Miya Mouri; Satoshi Yamamoto; Reiichi Ishikura; Tomonori Terada; Kazuma Noguchi; Shozo Hirota
Journal:  Jpn J Radiol       Date:  2016-02-26       Impact factor: 2.374

3.  [Malignant paranasal sinus tumors. Diagnosis, therapy and results].

Authors:  G Baier; C Völter; I Steigerwald; J Müller; K Schwager
Journal:  HNO       Date:  2005-11       Impact factor: 1.284

4.  The treatment of advanced sinonasal malignancies with pre-operative intra-arterial cisplatin and concurrent radiation.

Authors:  L Madison Michael; Jeffrey M Sorenson; Sandeep Samant; Jon H Robertson
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

5.  Primary sphenoid sinus neoplasms: a report of four cases with common clinical presentation treated with transsphenoidal surgery and adjuvant therapies.

Authors:  Felice Esposito; Daniel F Kelly; Harry V Vinters; Antonio A F DeSalles; Joel Sercarz; Alessandra A Gorgulhos
Journal:  J Neurooncol       Date:  2006-02       Impact factor: 4.130

6.  Characterization of the tumor immune microenvironment of sinonasal squamous-cell carcinoma.

Authors:  Jeffrey T Gu; Natalie Claudio; Courtney Betts; Shamilene Sivagnanam; Mathew Geltzeiler; Ferdinando Pucci
Journal:  Int Forum Allergy Rhinol       Date:  2021-09-12       Impact factor: 3.858

Review 7.  Cancer of the paranasal sinuses.

Authors:  Sandeep Samant; Emma Kruger
Journal:  Curr Oncol Rep       Date:  2007-03       Impact factor: 5.075

8.  [Sinonasal tract malignancies : a 14-year single institution experience].

Authors:  A Schröck; F Göke; T van Bremen; R Kirsten; M Jakob; T Ehrenberg; M Kühnemund; A Gerstner; K W G Eichhorn
Journal:  HNO       Date:  2012-12       Impact factor: 1.284

9.  Sinonasal tract and nasopharyngeal adenoid cystic carcinoma: a clinicopathologic and immunophenotypic study of 86 cases.

Authors:  Lester D R Thompson; Carla Penner; Ngoc J Ho; Robert D Foss; Markku Miettinen; Jacqueline A Wieneke; Christopher A Moskaluk; Edward B Stelow
Journal:  Head Neck Pathol       Date:  2013-09-15

10.  The importance of early diagnosis in patients with maxillary sinus carcinoma.

Authors:  Matthias Kreppel; Ali-Farid Safi; Martin Scheer; Hans-Joachim Nickenig; Joachim Zöller; Simon Preuss; Moritz Meyer; Daniel Rothamel; Timo Dreiseidler
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-09-07       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.